All In Biotech

Drug Trial Radar · NCT03689374

A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes

Effect of Semaglutide Once-weekly Versus Insulin Aspart Three Times Daily, Both as Add on to Metformin and Optimised Insulin Glargine (U100) in Subjects With Type 2 Diabetes A 52-week, Multi-centre, Multinational, Open-label, Active-controlled, Two Armed, Parallel-group, Randomised Trial in Subjects With Type 2 Diabetes

Last checked: Nov 19, 2026Latest source record: Nov 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,274 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,274

Actual

Start

Oct 1, 2018

Primary completion

Feb 22, 2021

Study completion Feb 22, 2021

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Sep 28, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will compare the effect of semaglutide once weekly to insulin aspart 3 times daily as add on to metformin and insulin glargine in people with type 2 diabetes. Participants will either get insulin glargine and semaglutide or insulin glargine and insulin aspart - which treatment the participant get is decided by chance. Insulin glargine is taken once a day and semaglutide once a week. Insulin aspart is taken three times per day before a meal. All three medicines come in pre-filled pens for injection under the skin. The study will last for about 71 weeks. If participant's blood sugar gets under or over certain values participant will only participate in 14 weeks. The study doctor will inform the participant about this. The participant will have 15 clinic visits and 22 phone calls with the study doctor.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • SemaglutideDrug

    Subjects will receive subcutaneous (s.c., under the skin) injections of semaglutide once weekly (OW) with a dose of 0.25 mg. The dose should be increased after four weeks to 0.5 mg semaglutide. After 4 more weeks the dose can be increased to 1.0 mg semaglutide if the study doctor decides and further dose adjusted throughout the study.

  • Insulin aspartDrug

    Subjects should initiate treatment with 4U of Insulin aspart (s.c. injections) before each main meal, three times daily (TID). The dose will be adjusted individually based on pre-prandial and bedtime self measured plasma glucose (SMPG) from the preceding 3 days

  • Insulin glargine U100Drug

    Run-in period: Subjects will receive s.c. injections of IGlar U100 OD in accordance with the approved local label of IGlar U100. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.0-6.9 mmol/L)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Glycated Haemoglobin (HbA1c)Time frame: Baseline (week 0), week 52

Locations

210 sites in 21 countries. Site status is shown where the registry gives one.

  • Novo Nordisk Investigational Site

    Banja Luka, Bosnia and Herzegovina

  • Novo Nordisk Investigational Site

    Sarajevo, Bosnia and Herzegovina

  • Novo Nordisk Investigational Site

    Tuzla, Bosnia and Herzegovina

  • Novo Nordisk Investigational Site

    Burgas, Bulgaria

  • Novo Nordisk Investigational Site

    Byala, Bulgaria

  • Novo Nordisk Investigational Site

    Dimitrovgrad, Bulgaria

  • Novo Nordisk Investigational Site

    Plovdiv, Bulgaria

  • Novo Nordisk Investigational Site

    Rousse, Bulgaria

  • Novo Nordisk Investigational Site

    Sofia, Bulgaria

  • Novo Nordisk Investigational Site

    Stara Zagora, Bulgaria

  • Novo Nordisk Investigational Site

    Stara Zagora, Bulgaria

  • Novo Nordisk Investigational Site

    Varna, Bulgaria

  • Novo Nordisk Investigational Site

    Karlovac, Croatia

  • Novo Nordisk Investigational Site

    Osijek, Croatia

  • Novo Nordisk Investigational Site

    Pula, Croatia

  • Novo Nordisk Investigational Site

    Rijeka, Croatia

  • Novo Nordisk Investigational Site

    Varaždin, Croatia

  • Novo Nordisk Investigational Site

    Zagreb, Croatia

  • Novo Nordisk Investigational Site

    Beroun, Czechia

  • Novo Nordisk Investigational Site

    Brno, Czechia

  • Novo Nordisk Investigational Site

    Kladno - Krocehlavy, Czechia

  • Novo Nordisk Investigational Site

    Mladá Boleslav, Czechia

  • Novo Nordisk Investigational Site

    Náchod, Czechia

  • Novo Nordisk Investigational Site

    Olomouc, Czechia

  • Novo Nordisk Investigational Site

    Pilsen, Czechia

  • Novo Nordisk Investigational Site

    Prostějov, Czechia

  • Novo Nordisk Investigational Site

    Pärnu, Estonia

  • Novo Nordisk Investigational Site

    Tallinn, Estonia

  • Novo Nordisk Investigational Site

    Tallinn, Estonia

  • Novo Nordisk Investigational Site

    Tallinn, Estonia

  • Novo Nordisk Investigational Site

    Viljandi, Estonia

  • Novo Nordisk Investigational Site

    Bad Kreuznach, Germany

  • Novo Nordisk Investigational Site

    Bad Mergentheim, Germany

  • Novo Nordisk Investigational Site

    Berlin, Germany

  • Novo Nordisk Investigational Site

    Berlin, Germany

  • Novo Nordisk Investigational Site

    Berlin, Germany

  • Novo Nordisk Investigational Site

    Berlin, Germany

  • Novo Nordisk Investigational Site

    Eisenach, Germany

  • Novo Nordisk Investigational Site

    Essen, Germany

  • Novo Nordisk Investigational Site

    Essen, Germany

Showing 40 of 210 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.